An important part of the Photopheresis therapy is connected with the use of a photosensitizer / photoactivator (8-MOP) in order to treat the collected white blood cells. The substance, in combination with the irradiation with UVA light, enables the therapy to become effective in the treatment of various diseases.
Recently the Austrian pharmaceutical manufacturer GL Pharma has received the official approval for the liquid form of 8-MOP (8-Methoxypsoralene) in Austria, which is now available.
For further general information and/or information concerning ordering please contact our customer service department (firstname.lastname@example.org), which will be pleased to assist with any questions and provide you with all relevant contact information.
Photo Immune Therapy (UVA Radiation) with the UVA PIT System has become a standard procedure performed in many treatment centres around the world.
One reason why the treatment has become this successful is the benefits of this procedure for the patient. Among others they include more safety and more patient comfort due to the fact that it is an ex vivo treatment – the patient is not connected to the system and therefore also not during the irradiation of the buffy coat.
This means that the time exposure for the patient is reduced significantly and individual freedom to customise the amount of time between apheresis phase and reinfusion to the patient is given.
Less connection to the device – more time for the patient
Due to the easy understandable technique and operation of the system, this can be achieved by any trained operator of the UVA PIT System.
Med Tech Solutions provides operating instruction and training, gives technical advice and trains its local disributors in order to ensure the best possible qualification for handling the system.
Please contact us for further information, our customer service department is at your disposal for any questions or requests.
The treatment of photopheresis (also known as extracorporeal photopheresis or ECP) is a therapy where the patient’s white blood cells (buffy coat) are collected by an apheresis system, treated with a photosensitizer / photoactivator and subsequently being irradiated with UVA light in the therapy system.
White blood cells
The procedure itself has been developed by Dr. Richard Edelson in 1987 and was introduced to the medical experts in the New England Journal of Medicine¹. The first medical equipment for photopheresis was commerically introduced by Therakos Inc.
Med Tech Solutions GmbH developed an own 2-Step-System for ECP in 2004.
Nowadays photopheresis is frequently used to treat different auto immune diseases, mainly GvHD, CTLC and SOT.
More information can be found on our homepage in the category „The Treatment“.
¹Edelson, R., Berger, C., Gasparro, F., et al. (1987): „Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.“ New England Journal of Medicine Feb. 5th 1987; 316(6); 297-303.